[go: up one dir, main page]

WO2016004280A3 - Inhibiteurs de tyrosine kinase de bruton - Google Patents

Inhibiteurs de tyrosine kinase de bruton Download PDF

Info

Publication number
WO2016004280A3
WO2016004280A3 PCT/US2015/038947 US2015038947W WO2016004280A3 WO 2016004280 A3 WO2016004280 A3 WO 2016004280A3 US 2015038947 W US2015038947 W US 2015038947W WO 2016004280 A3 WO2016004280 A3 WO 2016004280A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitors
btk
tyrosine kinase
bruton
irreversible
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2015/038947
Other languages
English (en)
Other versions
WO2016004280A2 (fr
Inventor
Wei Chen
Zhaozhong J. Jia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacyclics LLC
Original Assignee
Pharmacyclics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacyclics LLC filed Critical Pharmacyclics LLC
Publication of WO2016004280A2 publication Critical patent/WO2016004280A2/fr
Publication of WO2016004280A3 publication Critical patent/WO2016004280A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des composés hétéroaryle en tant qu'inhibiteurs de kinase. Des méthodes de synthèse de tels inhibiteurs et des méthodes d'utilisation de ces inhibiteurs dans le traitement de maladies sont également décrits.
PCT/US2015/038947 2014-07-02 2015-07-02 Inhibiteurs de tyrosine kinase de bruton Ceased WO2016004280A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462019977P 2014-07-02 2014-07-02
US62/019,977 2014-07-02

Publications (2)

Publication Number Publication Date
WO2016004280A2 WO2016004280A2 (fr) 2016-01-07
WO2016004280A3 true WO2016004280A3 (fr) 2016-03-10

Family

ID=55020101

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/038947 Ceased WO2016004280A2 (fr) 2014-07-02 2015-07-02 Inhibiteurs de tyrosine kinase de bruton

Country Status (1)

Country Link
WO (1) WO2016004280A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116808044A (zh) * 2018-06-15 2023-09-29 汉达癌症医药责任有限公司 激酶抑制剂的盐类及其组合物
EP3886854A4 (fr) 2018-11-30 2022-07-06 Nuvation Bio Inc. Composés pyrrole et pyrazole et leurs procédés d'utilisation
EP3966204B1 (fr) 2019-05-10 2024-11-27 Henan Zhiwei Biomedicine Co., Ltd. 1-amino-1h-imidazole-5-carboxamide substitué utilisé en tant qu'inhibiteurs de la tyrosine kinase de bruton

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030100768A1 (en) * 2000-12-13 2003-05-29 Han Amy Qi Imidazolidinones and their related derivatives as hepatitis C virus NS3 protease inhibitors
WO2014082598A1 (fr) * 2012-11-30 2014-06-05 Centaurus Biopharma Co., Ltd. Inhibiteurs de la tyrosine kinase de bruton

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030100768A1 (en) * 2000-12-13 2003-05-29 Han Amy Qi Imidazolidinones and their related derivatives as hepatitis C virus NS3 protease inhibitors
WO2014082598A1 (fr) * 2012-11-30 2014-06-05 Centaurus Biopharma Co., Ltd. Inhibiteurs de la tyrosine kinase de bruton

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HAHM ET AL.: "An Efficient Synthesis of Enantiomerically Pure Functionalized Imidazolidin-2-ones from Chiral Aziridines: Supplementary Information.", THE ROYAL SCIENCE OF CHEMISTRY, 2005, Retrieved from the Internet <URL:http://www.rsc.org/suppdata/cc/b5/b503750f/b503750f.pdf> [retrieved on 20150902] *

Also Published As

Publication number Publication date
WO2016004280A2 (fr) 2016-01-07

Similar Documents

Publication Publication Date Title
MX2022002579A (es) Compuestos de aminotiazol como inhibidores de c- kit.
TN2015000417A1 (en) Heteroaryl compounds and uses thereof
WO2016004305A3 (fr) Inhibiteurs de la tyrosine kinase de bruton
PH12017550028A1 (en) Solid forms of an ask1 inhibitor
NZ729603A (en) Heteroaryl compounds as btk inhibitors and uses thereof
WO2016196776A3 (fr) Inhibiteurs de la tyrosine kinase de bruton
IL248546A0 (en) A polysubstituted fluorine compound as a proton tyrosine kinase inhibitor
WO2015048689A8 (fr) Inhibiteurs de la tyrosine kinase de bruton
MX2019001125A (es) Inhibidores de cinasa macrociclica.
MX387097B (es) Formulaciones oftalmicas de inhibidores de tirosina quinasa, metodos de uso de las mismas y metodos de preparacion de las mismas.
HK1252378A1 (zh) 酪氨酸激酶抑制剂
WO2016105525A3 (fr) Nouvelles pyrimidines en tant qu&#39;inhibiteurs d&#39;egfr et procédés de traitement de troubles
MY191581A (en) Anti-pd-1 antibodies
HK1220184A1 (zh) 用於治疗癌症的作为癌症干细胞途径激酶抑制剂的3-(芳基或杂芳基)甲基吲哚-2-酮衍生物
PH12017502236A1 (en) 2-(pyrazolopyridin-3-yl)pyrimidine derivatives as jak inhibitors
HK1220355A1 (zh) Mk2抑制劑和其用途
HK1221661A1 (zh) Acc抑制剂和其用途
WO2015001504A3 (fr) Formulations d&#39;anticorps et procédés correspondants
HUE060152T2 (hu) 4-(3H-indol-5-il)-N-(piridin-2-il)pirimidin-2-amin-származékok mint proteinkináz inhibitorok, elõállítási eljárásuk és gyógyászati alkalmazásuk
MX2017003930A (es) Derivados de aminotriazina utiles como compuestos inhibidores de la cinasa de union a tank.
PH12016502523A1 (en) Crystalline salts of (s)-6-((1-acetylpiperidin-4-yl)amino)-n-(3-(3,4-dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)pyrimidine-4-carboxamide
EA201591794A1 (ru) Макроциклические ингибиторы соль-индуцируемых киназ
WO2014145485A3 (fr) Modulateurs de map kinase et utilisations de ceux-ci
AU2015316010A8 (en) Crystalline forms of 6-( (6, 7-dimethoxyquinazolin-4-yl) oxy) -N,2-dimethylbenzofuran-3-carboxamide
HK1254231A1 (zh) 米托-和厚朴酚化合物及其合成方法和用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15815146

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15815146

Country of ref document: EP

Kind code of ref document: A2